CoChat

A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

TURNER, IAN B., MYSZOR, MARGARET, MITCHISON, HARRIET C., BENNETT, MARK K., BURT, ALISTAIR D., JAMES, OLIVER F. W. · 1994 · Journal of Gastroenterology and Hepatology
Cited by 47

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Abstract Forty‐six patients with primary biliary cirrhosis from a single centre were studied in a randomized placebo‐controlled trial to determine the effectiveness of ursodeoxycholic acid (UDCA) over a 2 year period. The two groups were well‐matched at baseline. For each parameter, by calculating the difference between the median changes with time between the UDCA group and the placebo group, it was found that from entry, with respect to placebo, there were differences between median changes (MCD) favouring the UDCA group in bilirubin {MCD 5 μmol/L [95% confidence interval (CI) 1 to 12] at 1 year and 5 μmol/L (95% CI 1 to 9) at 2 years}, alkaline phosphatase MCD 242 iu/L (95% CI 107 to 360) at 1 year and 268 iu/L (95% CI 146 to 424) at 2 years and aspartate aminotransferase MCD 26 iu/L (95% CI 12 to 41) at 1 year and 37 iu/L (95% CI 16 to 64) at 2 years. Within the UDCA group, there was long‐term fall in alkaline phosphatase [median fall 116 iu/L (95% CI 93 to 378) at 2 years and aspartate aminotransferase [median fall 18 iu/L (95% CI 6 to 47) at 2 years; however, the major change in bilirubin was a modest rise over 2 years in the placebo group [median rise 2 μmol/L (95% CI 1 to 9)]. Changes in albumin, prothrombin ratio and immunoglobulins were generally minor and not significant. Ursodeoxycholic acid did not generally influence stage progression or histological features, although a smaller percentage of non‐cirrhotic patients were documented as having developed cirrhosis on UDCA compared to placebo (14 vs 57%) over the 2 years. There appeared to be no consistent effect on pruritus and general well‐being. The medication was well‐tolerated and safe. In conclusion, UDCA appears to have beneficial effects on some serum biochemical markers in primary biliary cirrhosis and so may have a role in retarding disease progression. It could be useful in combination with an immunosuppressive or an anti‐fibrotic agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1746.1994.tb01237.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 45

  1. 10.1016/0016-5085(89)91698-3 · DOI · Paper page
  2. 10.1016/S0140-6736(87)91610-2 · DOI · Paper page
  3. 10.1002/hep.1840100404 · DOI · Paper page
  4. Matsuzaki Y., 1990, Improvement of biliary enzyme levels and itching as a result of long‐term administration of ursodeoxycholic acid in primary biliary cirrhosis, Am. J. Gastroenterol., 85, 15
  5. 10.1016/0168-8278(90)90134-D · DOI
  6. 10.1002/hep.1840120308 · DOI · Paper page
  7. Fisher M. M., 1986, Influence of ursodeoxycholic acid (UDCA) on biochemical parameters in cholestatic liver disease (Abstr.), Gastroenterology, 90, 1725
  8. Hadziyannis S. J., 1989, A randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.), Hepatology, 10, 580
  9. Podda M., 1989, Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): A double‐blind multicenter trial (Abstr.), Hepatology, 10, 639
  10. Heathcote E. J. L., 1992, The Canadian multi‐centre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.), Hepatology, 16, 91A
  11. Lindor K. D. L., 1992, Ursodeoxycholic acid is beneficial therapy for patients with primary biliary cirrhosis (Abstr.), Hepatology, 16, 91A
  12. Hayashi H., 1988, Ursodeoxycholic acid (UDCA) (Abstr.). reduces secondary liver damage in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (Abstr.), Hepatology, 8, 1417
  13. Wiesner R. H., 1990, Ursodeoxycholic acid therapy for primary biliary cirrhosis: Progression of disease despite near normalization of biochemical liver tests (Abstr.), Hepatology, 12, 843
  14. Myszor M., 1990, No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year controlled pilot study (Abstr.), Hepatology, 12, 415
  15. 10.1136/bmj.297.6662.1501 · DOI · Paper page
  16. 10.1097/00004836-199004000-00012 · DOI · Paper page
  17. 10.1002/hep.1840080339 · DOI
  18. Gardner M. J., 1989, Statistics with Confidence, 140
  19. 10.1056/NEJM198612043152304 · DOI · Paper page
  20. 10.1016/S0016-5085(19)33223-8 · DOI · Paper page
  21. Palmer R. H., 1972, Bile acids, liver injury, and liver disease, Arch. Intern. Med., 130, 606, 10.1001/archinte.1972.03650040130012 · doi:10.1001/archinte.1972.03650040130012 · Paper page
  22. Dryzka H., 1976, Hepatic toxicity in the Rhesus monkey treated with chenodeoxycholic acid for six months — Biochemical and ultrastructual studies, Gastroenterology, 70, 93, 10.1016/S0016-5085(76)80409-X · DOI
  23. Yousef I. M., 1981, Lithocholate cholestasis‐sulfated glycolithocholate‐induced intrahepatic cholestasis in rats, Gastroenterology, 80, 233, 10.1016/0016-5085(81)90709-5 · DOI
  24. 10.1172/JCI111356 · DOI
  25. 10.1002/hep.1840040416 · DOI · Paper page
  26. Kitani K., 1985, Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat, Am. J. Physiol., 248, G407
  27. 10.1002/hep.1840120523 · DOI · Paper page
  28. 10.1016/0168-8278(90)90133-C · DOI
  29. 10.1016/0016-5085(91)90602-H · DOI · Paper page
  30. Greim H., 1972, Mechanisms of cholestasis. 6. Bile acids in human livers with or without biliary obstruction, Gastroenterology, 63, 846
  31. 10.1016/0016-5085(78)90068-9 · DOI
  32. 10.1016/S0016-5085(83)80004-3 · DOI
  33. 10.1007/BF01317087 · doi:10.1007/bf01317087
  34. 10.1002/hep.1840120307 · DOI · Paper page
  35. Hadziyannis S. J., 1991, Bile Acids as Therapeutic Agents, 287
  36. 10.1016/0016-5085(90)90834-N · DOI
  37. 10.1002/hep.1840120521 · DOI · Paper page
  38. Güldütuna S., 1990, Ursodeoxycholic acid protects basolateral liver plasma membranes against toxic bile acid salts (Abstr.), Hepatology, 12, 997
  39. 10.1002/hep.1840140527 · DOI · Paper page
  40. Thielmann L., 1991, Bile Acids as Therapeutic Agents, 243
  41. 10.1002/hep.1840110104 · DOI · Paper page
  42. 10.1002/hep.1840160213 · DOI · Paper page
  43. 10.1002/hep.1840160213 · DOI · Paper page
  44. 10.1002/hep.1840160317 · DOI
  45. 10.1016/0016-5085(93)90440-N · DOI

Cited by

See all 47

Metadata

Authors
TURNER, I. B., MYSZOR, M., MITCHISON, H. C., BENNETT, M. K., BURT, A. D., & JAMES, O. F. W.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
1994-04
Volume
9
Issue
2
Pages
162-168
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2071178569
Cited by
47
References
4
FWCI
2.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. https://app.cochat.ai/papers/10.1111/j.1440-1746.1994.tb01237.x
The paper
TURNER, I. B., MYSZOR, M., MITCHISON, H. C., BENNETT, M. K., BURT, A. D., & JAMES, O. F. W. (1994). A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.1994.tb01237.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.